Please login to the form below

Not currently logged in
Email:
Password:

kinase inhibitor

This page shows the latest kinase inhibitor news and features for those working in and with pharma, biotech and healthcare.

BMS CEO tackles investor ‘frustrations’ on immuno-oncology

BMS CEO tackles investor ‘frustrations’ on immuno-oncology

BMS was the pathfinder for the checkpoint inhibitor market with its CTLA4 inhibitor Yervoy (ipilimumab) and PD-1 blocker Opdivo (nivolumab), However, it has since lost ground to rival Merck ... inhibitor Bavencio (avelumab) – both given in tandem with

Latest news

  • Merck’s Bavencio joins first-line kidney cancer face-off Merck’s Bavencio joins first-line kidney cancer face-off

    The JAVELIN Renal 101 study reported at this week’s ESMO conference paired Merck’s immuno-oncology drug Bavencio (avelumab) with Pfizer’s tyrosine kinase inhibitor Inlyta (axitinib), and revealed a ... inhibitor and TKI has emerged as an “early

  • A look ahead to key trial readouts at ESMO A look ahead to key trial readouts at ESMO

    101 study, the first time that a checkpoint inhibitor has shown an increase in progression-free survival (PFS) when combined with a tyrosine kinase inhibitor – in this case Pfizer’s Inlyta ... for its MAGE-A10-targeting cell therapy in non-small cell

  • FDA approval gained, Pfizer sets sights on first-line NSCLC market FDA approval gained, Pfizer sets sights on first-line NSCLC market

    Pfizer’s gruelling trek to bring EGFR inhibitor dacomitinib to market has finally paid off, with the FDA approving it as a first-line therapy for non-small cell lung cancer ... NSCLC). The second-generation EGFR tyrosine kinase inhibitor has been shown

  • BMS psoriasis drug hits the mark in phase II BMS psoriasis drug hits the mark in phase II

    BMS psoriasis drug hits the mark in phase II. Tyrosine kinase 2 (Tyk2) inhibitors could play major role. ... The phase II trial of tyrosine kinase 2 (Tyk2) inhibitor BMS-986165 showed a level of efficacy that was greater than other oral therapies for

  • CTI slumps as Servier-partnered lymphoma drug fails CTI slumps as Servier-partnered lymphoma drug fails

    Thankfully for CTI, it’s been making progress on main pipeline candidate pacritinib, an orally-active kinase inhibitor that targets JAK2, FLT3, IRAK1 and CSF1R and is in phase III testing

More from news
Approximately 1 fully matching, plus 168 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Acquisition company - remaining 90%. 9, 000. Impact Biomedicines/ Celgene. Fedratinib, highly selective JAK2 kinase inhibitor for myelofibrosis (p3) and polycythemia vera. ... This acquisition brings tucatinib, an oral tyrosine kinase inhibitor that is

  • Accelerating innovation Accelerating innovation

    While the company waits to hear from the EMA, there is also work underway to explore the use of Ipsen’s tyrosine-kinase inhibitor (TKI) Cabometyx in combination with some of

  • Deal Watch September 2016 Deal Watch September 2016

    No financial terms were disclosed. Genentech signed an exclusive licence [global excluding South Korea] with Hanmi Pharmaceutical to develop and market HM95573, a pan-RAF inhibitor. ... 1, 000+. Hanmi / Genentech. Licence. HM95573, a selective

  • Deal Watch June 2016 Deal Watch June 2016

    acquisition assets. 350. CrystalGenomics/ Aptose Biosciences. CG026806 inhibitor of Bruton's tyrosine kinase, FMS-like tyrosine kinase 3 and Aurora kinases (preclinical). † ... acquisition company. 105. Nektar Therapeutics/ Daiichi Sankyo Europe.

  • Deal Watch May 2016 Deal Watch May 2016

    Paying a 55% premium at $99.25 per share, the acquisition brings crisaborole, a topical PDE4 inhibitor for mild to moderate atopic dermatitis (eczema) with estimated peak sales of $2bn. ... 282. Carna Biosciences/ ProNAi Therapeutics. Licence. $0.9m

More from intelligence
Approximately 0 fully matching, plus 19 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...

Infographics